Day One Announces First Patient Dosed in Phase 2 Monotherapy Study in RAF-altered Solid Tumors

NEXT STORY
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
PREV STORY
Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Point of Care (POC) Molecular Diagnostics Market Worth $2.32 billion by 2027- Exclusive Report by Meticulous Research®

author_avatar
NASDAQ Market News

FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.

FIT Biotech Oy                                                                                               Press Release July 3rd 2018, 08.30 EET FIT Biotech webcasts the ...

author_avatar
NASDAQ Market News

Athenex Provides an Update on Oral Paclitaxel FDA Meeting

author_avatar
NASDAQ Market News